Advertisement
Advertisement
Trending on Dermatology Times
1
5 Dermatology Approvals to Know from the First Half of 2026
2
Dermatology Times Spot Test: July 12, 2026
3
Guselkumab's CD64 Binding Offers Targeted IL-23 Inhibition in PsA
4
Phase 1b Trial of FB102 Demonstrates Significant Facial Repigmentation and Sustained Vitiligo Response
5